Journal of SAFOMS

Register      Login

VOLUME 2 , ISSUE 2 ( July-December, 2014 ) > List of Articles

RESEARCH ARTICLE

Medical Management of Dysfunctional Menorrhagia: Is Ormeloxifene a Safe and Efficacious Therapeutic Choice?

Nidhi Gupta

Citation Information : Gupta N. Medical Management of Dysfunctional Menorrhagia: Is Ormeloxifene a Safe and Efficacious Therapeutic Choice?. J South Asian Feder Menopause Soc 2014; 2 (2):65-70.

DOI: 10.5005/jp-journals-10032-1044

Published Online: 01-12-2014

Copyright Statement:  Copyright © 2014; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Menstrual blood loss-a population study. Acta Obstet Gynecol Scand 1966; 45:320-351.
  2. Therapeutic use of Levonorgestel releasing intrauterine system in women with menorrhagia. A pilot study. Contraception 2002;65:325-328.
  3. Assessment of menstrual blood loss using a pictoral chart. Br J Obstet Gynaecol 1990; 97:734-739.
  4. Treatment of dysfunctional uterine bleeding. Am enorrhea need not be the end point BMJ 1995;310:802.
  5. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;4:CD001501.
  6. Medical management of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000;27:287-304.
  7. Treating menorrhagia in primary care: an overview of drug trials and a survey of prescribing practice. Int J Tech Assess Health Care 1995;456-471.
  8. Retrospective valuation of the long-term outcomes following conservative management of menorrhagia in ovulatory women. LSOC Obstet Gynecol Can 1999;2:155-163.
  9. The Levonorgestrel—releasing intrauterine system as an alternative to hysterectomy in perimenopausal women contraception 2007;75:5152-5154.
  10. Optimization of contraceptive dosage regimen of centchromam. Contraception 2001;63:47-51.
  11. A selective estrogen receptor modulator, as a contraceptive and for the management of hormone related clinical disorders. Med Res Rw 2001;21: 303-347.
  12. Centchroman: a nonsteroidal anti cancer agent for advanced breast cancer phase II study. Int J Cancer 1989;43:781-783.
  13. Mode of action of a new nonsteroidal postcoital antifertility agent (centchroman 67/20 CDRI) in rats, Contraception 1974;9:279-289.
  14. Effect of intravaginal instillation of some nonsteroidal oral anti-infertility agent on pregnancy in rats. Ind J Exp Biol 1974;12:370-371.
  15. Determination of menstrual blood loss. Scand J Clin Lab Invest 1964;16:244-248.
  16. Management of dysfunctional uterine bleeding. Drugs 1992;44:578-584.
  17. Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception 1995;52:297-300.
  18. Treatment of menorrhagia during menstruation. Randomized control trial of ethamsylate, Mefenamic acid and tranexamic acid. BMJ 1996;313:579-582.
  19. A comparison of Flurbiprofen, tranexamic acid and a Levonorgestral releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-883.
  20. Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynecol Res 2009;35(4):746-752.
  21. Ormeloxifene a selective estrogen receptor modulator, for treatment of dysfunctional menorrhagia. J Obstet Gynecol Ind 2004;54(1):56-59.
  22. Efficacy of a selective estrogen receptor modulator ‘ormeloxifene’ in management of dysfunctional uterine bleeding. J South Asian Fed Obstet Gynec 2010;2(3):207-211.
  23. Contraceptive and noncontraceptive benefits of centchroman. Asian J Obstet Gynecol Practice 1996;1:65-71.
  24. Clinical pharmacokinetics and interaction of centchroman a mini review. Contraception 2010;81(4):275-280.
  25. Selective estrogen receptor modulators (SERMS). Online J Smt NHL Municipal Med Coll. Ahmedabad. Available at: http://www:nhlmmcgym.com/selectiveestrogen.htm.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.